We found that artesunate failed to reduce Aβ pathology in hippocampus or cortex of Picalmlox/lox; Cdh5-Cre; 5XFAD mice as indicated by comparable Aβ42 or Aβ40 levels (Fig. 4F, G), Aβ load and thioflavin S-positive amyloid load (Fig. 4H-K) in artesunate-treated compared to vehicle-treated 5XFAD mice lacking endothelial PICALM. Here, PICALM is linked to amyloidosis.